Todo *et al*. described a case of myasthenia gravis (MG) with myositis and myocarditis in a patient who received pembrolizumab for recurrent bladder cancer.[1](#iju512132-bib-0001){ref-type="ref"} Neuromuscular immune‐related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are relatively rare. A study reported that only 12 (0.12%) patients had MG among 9869 patients treated with nivolumab in Japan.[2](#iju512132-bib-0002){ref-type="ref"}

Although concomitant myositis or myocarditis is infrequently observed in patients with idiopathic MG, they were often observed as irAEs during ICI treatment in patients with MG, as in this case.[2](#iju512132-bib-0002){ref-type="ref"} As mentioned by the authors, these neuromuscular irAEs can induce fatal events; therefore, cardiac examination should be performed when MG is suspected during ICI treatment, and the hospital should organize a comprehensive management team before starting the ICI treatment.

Another interesting point in this case is that only a single administration of pembrolizumab achieved almost complete response, which lasted \>6 months after its discontinuation. Several studies demonstrated that irAE development was positively associated with the survival outcome of ICI treatment.[3](#iju512132-bib-0003){ref-type="ref"}, [4](#iju512132-bib-0004){ref-type="ref"} Furthermore, oncological outcomes were not different between patients who discontinued ICI treatment due to adverse events and those who did not.[5](#iju512132-bib-0005){ref-type="ref"} In terms of ICI re‐treatment after irAE, Santini *et al*. demonstrated that 52% of patients in the re‐treatment cohort experienced irAE recurrence (initial irAEs, 26%; new irAEs, 26%).[6](#iju512132-bib-0006){ref-type="ref"} It is recommended to treat cases of bladder cancer progression with another treatment such as taxane‐based chemotherapy rather than ICI re‐treatment because of the frequent recurrence of irAE.
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